IMM
BADImmuPharma Raises £25,000 Through Warrant Exercise
The biopharmaceutical company has raised £25,000 through the exercise of warrants, issuing new shares at a 66.4% discount to the previous closing price.
ImmuPharma
12.90GBX
12.17%
Market Cap
64.46M
Volume
7.14M
78% of avg
P/E Ratio
-3.81
EPS (TTM)
-3.39
Beta
2.58
Day Range
10.60p - 14.00p
52 Week Range
0.85p12.90p19.40p
12.90p
Upcoming Events
IMM
NEUTRALImmuPharma Announces Exercise of Warrants
The biopharmaceutical company has received notice of the exercise of 2.5 million warrants, representing 0.5% of the enlarged share capital.
IMM
NEUTRALImmuPharma Appoints New Chief Scientific Officer and Head of R&D
The biopharmaceutical company has made key appointments to its R&D leadership team.
IMM
NEUTRALImmuPharma Files New Patent Application for P140
The biopharmaceutical company has filed a new patent application for its lead asset P140, which could provide 20 years of commercial exclusivity and enable a precision approach to treating autoimmune diseases.
IMM
NEUTRALImmuPharma Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
IMM
BADImmuPharma Reports Widening Losses in H1 2025 Amid Scientific Progress
The biopharmaceutical firm reported widening losses and decreased cash reserves in H1 2025, despite significant advancements in its P140 technology platform for autoimmune diseases.
IMM
NEUTRALImmuPharma Announces Change in Shareholding
The biopharmaceutical company has announced a change in its major shareholding.
IMM
NEUTRALImmuPharma Announces AGM and Annual Report
The biopharmaceutical company has announced the details of its upcoming Annual General Meeting and the availability of its Annual Report and Accounts.
IMM
NEUTRALImmuPharma Reports Progress in P140 Research Amid Continued Losses
The biopharmaceutical firm reported advancements in its P140 autoimmune research program, alongside reduced annual losses. However, cash reserves remain low, highlighting ongoing financial challenges in its pre-revenue stage.
IMM
NEUTRALImmuPharma Extends Warrants in Incanthera to 2025
The biopharmaceutical company has agreed to extend the exercise period of warrants in Incanthera plc to September 2025.